Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals

Xu, Yuping

doi:10.4251/wjgo.v8.i2.165

Cited by 14 publications

(12 citation statements)

References 96 publications

(164 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Molecular tracers such as F-fluorodeoxyglucose used in positron emission tomography (PET) and CT imaging hold promise as a powerful diagnostic tool for potentially malignant tumours, although a high false-positive rate in hyperglycaemic patients must be addressed [10]. …”

Section: Current Shortcomings In the Diagnosis And Treatment Of Pancrmentioning

confidence: 99%

Tumour-derived exosomes as a signature of pancreatic cancer - liquid biopsies as indicators of tumour progression

et al. 2016

View full text Add to dashboard Cite

Pancreatic cancer is the fourth most common cause of death due to cancer in the world. It is known to have a poor prognosis, mostly because early stages of the disease are generally asymptomatic. Progress in pancreatic cancer research has been slow, leaving several fundamental questions pertaining to diagnosis and treatment unanswered. Recent studies highlight the putative utility of tissue-specific vesicles (i.e. extracellular vesicles) in the diagnosis of disease onset and treatment monitoring in pancreatic cancer. Extracellular vesicles are membrane-limited structures derived from the cell membrane. They contain specific molecules including proteins, mRNA, microRNAs and non-coding RNAs that are secreted in the extracellular space. Extracellular vesicles can be classified according to their size and/or origin into microvesicles (∼150-1000 nm) and exosomes (∼40-120 nm). Microvesicles are released by budding from the plasmatic membrane, whereas exosomes are released via the endocytic pathway by fusion of multivesicular bodies with the plasmatic membrane. This endosomal origin means that exosomes contain an abundance of cell-specific biomolecules which may act as a fingerprint of the cell of origin. In this review, we discuss our current knowledge in the diagnosis and treatment of pancreatic cancer, particularly the potential role of EVs in these facets of disease management. In particular, we suggest that as exosomes contain cellular protein and RNA molecules in a cell type-specific manner, they may provide extensive information about the signature of the tumour and pancreatic cancer progression.

show abstract

Section: Current Shortcomings In the Diagnosis And Treatment Of Pancrmentioning

confidence: 99%

Tumour-derived exosomes as a signature of pancreatic cancer - liquid biopsies as indicators of tumour progression

et al. 2016

View full text Add to dashboard Cite

show abstract

“…However, 18 F-FDG PET/CT still has several drawbacks in detecting pancreatic cancer. The chronic and acute pancreatitis both have high 18 F-FDG uptake, leading to false-positive interpretations, and the application of 18 F-FDG PET in hyperglycemic patients also is not ideal, because the uptake of imaging agent is suppressed as a result of high serum glucose competitive inhibition 5 , 6 . Therefore, the development of new molecular probes, which can target pancreatic cancer specifically and overcome the limitations of 18 F-FDG to some extent, are urgently needed and have great clinical significance.…”

Section: Introductionmentioning

confidence: 99%

Preliminary study on SPECT/CT imaging of pancreatic cancer xenografts by targeting integrin α5 in pancreatic stellate cells

Wang¹,

Ye²,

Li³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

Background: Integrin α5 (ITGA5) is overexpressed specifically in pancreatic cancer stroma, specially, in the activated pancreatic stellate cells (PSCs). Molecular imaging of pancreatic cancer via targeting PSCs has its advantages. Purpose: This study aims to investigate the feasibility of ITGA5-targeted SPECT/CT imaging of pancreatic cancer by targeting PSCs. Methods: ITGA5 expression in PSCs treated without or with pancreatic cancer SW1990 cells conditioned medium (SW1990-CM) was assessed by western blotting and immunofluorescence staining. ITGA5 specific inhibitor AV3 peptide was radiolabeled with 125 I to synthesize 125 I-AV3, and the labeling rate, in vitro stability and cellular uptake were further investigated. SW1990 cells alone or with PSCs were injected subcutaneously on the left and right lower limbs of nude mice respectively to establish pancreatic cancer xenograft model, and then 125 I-AV3 SPECT/CT imaging of pancreatic cancer-bearing nude mice was performed. The expression of ITGA5 in tumors was detected by immunohistochemical (IHC) staining. Results: 125 I-AV3 has an excellent labeling rate and good in vitro stability. After treated with SW1990-CM, PSCs had an increased expression of ITGA5 and higher 125 I-AV3 uptake. SPECT/CT imaging study showed that 125 I-AV3 was mainly accumulated in the right xenografts (co-injection of cancer cells and PSCs), while the left xenografts tumors have a poor imaging. Moreover, the uptake of radiotracer in both side tumors was inhibited significantly after the non-radiolabeled AV3 pretreatment. IHC staining showed that SW1990 + PSCs tumor has a higher positive rate of ITGA5 than SW1990 tumor. Conclusion: The preliminary study suggests that 125 I-AV3 can be used for SPECT/CT imaging of pancreatic cancer via targeting ITGA5 in PSCs, which is independent of the state of cancer cells and may have a special meaning.

show abstract

“…Pancreatic cancer is considered one of the most aggressive and fatal malignant gastrointestinal tract tumors, and its morbidity and mortality rates are gradually increasing [ 1 ]. Even with improved diagnostic strategies and the best therapeutic intervention available today, the 5-year survival rate for the patients remains alarmingly dismal, at less than 5% [ 2 , 3 ]. The latest epidemiological investigation showed that pancreatic cancer accounts for 3% of cancer-related deaths worldwide, making it the 7 th most common cause of death induced by cancer worldwide [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Deoxyelephantopin induces apoptosis via oxidative stress and enhances gemcitabine sensitivity in vitro and in vivo through targeting the NF-κB signaling pathway in pancreatic cancer

Zhong

Huang

et al. 2020

Aging

View full text Add to dashboard Cite

Pancreatic cancer is a highly invasive malignant tumor of the digestive system with an unfavorable prognosis worldwide. This trait is thought to be largely attributed to chemoresistance. Chemotherapy is the only hope for patients with advanced pancreatic cancer. Therefore, seeking new effective chemotherapy drugs has become an urgent need. The purpose of our study was to explore whether deoxyelephantopin (DET), a sesquiterpene lactone, has a potential antitumor effect in pancreatic cancer. Additionally, the antitumor effects of DET alone or in combination with gemcitabine (GEM) and the potential mechanism of this combination were revealed. In vitro experiments showed that DET suppressed the proliferation, invasion and metastasis of pancreatic cancer cells, induced cell apoptosis via oxidative stress, and enhanced GEM sensitivity by inhibiting the NF-κB signaling pathway. Beyond that, in vivo experiments showed that DET not only inhibited pancreatic tumor growth and metastasis but also amplified the antitumor capacity of GEM, which was related to the downregulation of NF-κB and its downstream gene products. In summary, it is possible that DET could be developed as a single agent or combined with conventional chemotherapy drugs to improve the treatment of pancreatic cancer.

show abstract

Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals

Cited by 14 publications

References 96 publications

Tumour-derived exosomes as a signature of pancreatic cancer - liquid biopsies as indicators of tumour progression

Tumour-derived exosomes as a signature of pancreatic cancer - liquid biopsies as indicators of tumour progression

Preliminary study on SPECT/CT imaging of pancreatic cancer xenografts by targeting integrin α5 in pancreatic stellate cells

Deoxyelephantopin induces apoptosis via oxidative stress and enhances gemcitabine sensitivity in vitro and in vivo through targeting the NF-κB signaling pathway in pancreatic cancer

Contact Info

Product

Resources

About